Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-22-011508
Filing Date
2022-05-09
Accepted
2022-05-09 16:07:03
Documents
65
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q atos20220331_10q.htm   iXBRL 10-Q 783290
2 EXHIBIT 31.1 ex_353031.htm EX-31.1 11179
3 EXHIBIT 31.2 ex_353032.htm EX-31.2 11077
4 EXHIBIT 32.1 ex_353033.htm EX-32.1 5850
5 EXHIBIT 32.2 ex_353034.htm EX-32.2 6478
  Complete submission text file 0001437749-22-011508.txt   4112914

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA atos-20220331.xsd EX-101.SCH 47766
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atos-20220331_cal.xml EX-101.CAL 27033
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20220331_def.xml EX-101.DEF 305345
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20220331_lab.xml EX-101.LAB 267783
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20220331_pre.xml EX-101.PRE 331469
59 EXTRACTED XBRL INSTANCE DOCUMENT atos20220331_10q_htm.xml XML 460412
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35610 | Film No.: 22904906
SIC: 2834 Pharmaceutical Preparations